|View printer-friendly version|
|Lubrizol LifeSciences to Highlight Complex Drug Product Development and Manufacturing at Pharmapack 2018|
Lubrizol LifeSciences to Highlight Complex Drug Product Development and Manufacturing at Pharmapack 2018
CLEVELAND, February 7, 2018 - The Lubrizol Corporation's LifeSciences business announces it will participate in Europe's dedicated pharmaceutical packaging and drug delivery event in 2018. Specifically, Lubrizol LifeSciences will feature drug product development and manufacturing capabilities at Pharmapack 2018 (Stand #L10).
LifeSciences offers a comprehensive suite of services for the formulation, development and production of complex drug products such as micro- and nano-particulates, drug-eluting devices, suspensions and emulsions. LifeSciences provides comprehensive solutions by offering pharmaceutical excipients and drug product development, as well as clinical and commercial manufacturing capabilities for complex drug products, including drug-eluting devices.
Additionally, at Pharmapack, Lubrizol LifeSciences will highlight its previously stated investment in a new expanded commercial manufacturing facility. Announced in June 2017, this new space will accommodate both sterile and non-sterile products, highly potent compounds, controlled substances and organic solvent processing. Leveraging the company's knowledge in complex drug product development, the commercial manufacturing facility is adjacent to the existing facility, offering customers a seamless transition from early development through commercial supply.
UAbout Lubrizol LifeSciences
UAbout The Lubrizol Corporation
With headquarters in Wickliffe, Ohio, Lubrizol owns and operates manufacturing facilities in 17 countries, as well as sales and technical offices around the world. Founded in 1928, Lubrizol has approximately 8,300 employees worldwide. Revenues for 2016 were $6.5 billion. For more information, visit Lubrizol.com.